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Abstract: The study was conducted to evaluate the clinical and angiographic results of the 
implantation of the paclitaxel-eluting stent Meo:DrugStar ST in patients with symptomatic 
coronary artery disease. The Meo:DrugStar ST stent has a stainless steel stent platform with a 
homogenous non-biodegradable coating of paclitaxel mixed with a polyether-based biostable, 
monophase, and hemocompatible coating. Sixty patients with native coronary artery disease 
were included in the study. The Meo:DrugStar ST stents were implanted in 60 de novo lesions 
detected in these patients. Immediate and long-term clinical and angiographic follow-up results 
were evaluated. There was a high proportion of patients with hypertension (55%) according to 
JNC-VII. Mean stenosis ratio was 78 ± 13 %, mean implanted stent diameter was 3.0 ± 0.4 mm 
and mean length was 22 ± 5 mm. Restenosis was detected in 4 (10%) of those patients and 11 
(27.5%) of 40 patients had insigniﬁ  cant amount of restenosis.The results of this study indicate 
a potential beneﬁ  t of the Meo:DrugStar ST stent for the prevention of stent thrombosis and 
restenosis in these relatively high-risk patients.
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The development and widespread use of coronary stents has probably been the single 
most signiﬁ  cant advance in the ﬁ  eld of interventional cardiology over the last decade. 
The use of a stent at the time of coronary artery dilatation is now carried out in more 
than 70% of all intra-coronary angioplasty procedures and, in many ways, coronary 
angioplasty has become coronary stenting. Its exact role is still being debated and 
there is a proliferation of stent designs, stent technologies, and stent coatings which 
continue to challenge the interventional cardiologist to try and utilize them to their best 
ability. The increased cost of stenting represents ﬁ  nancial challenges that have been 
taken up to a greater or lesser extent in different health-care systems and countries 
(Serruys et al 1994).
A breakthrough occurred in early 2000 with the development of stents that eluted 
pharmacology agents directly into the vessel wall by means of a controlled release 
from a durable polymer coating. Various drug-eluting stents (DES) were developed, 
each varying in delivery platform, polymer coating (or absence of coating), and drug 
selected for elution (Pompa and Tulli 2006).
The paclitaxel-eluting stent (Meo:DrugStar ST, Germany) is a new DES. It has 
a stainless steel stent platform and a homogenous non-biodegradable coating of 
paclitaxel mixed with a polyether-based biostable, monophase, and hemocompatible 
coating. Paclitaxel release is completed within 28 days of implantation (Figure 1). Vascular Health and Risk Management 2008:4(1) 174
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This article describes the immediate and long-term clinical 
and angiographic results following implantation of the 
paxlitacel-eluting stent Meo:DrugStar ST.
The CYPHER® stent (Cordis Corporation, Miami Lakes, 
FL, USA) is composed of balloon-expandable stainless 
steel, a durable copolymer mixture of polyethylene-covinyl 
acetate (PEVA) and poly-n-butyl methacrylate (PBMA), and 
a sirolimus, which is a G1 cell cycle inhibitor that also has 
potent anti-inﬂ  ammatory properties. Using the commercially 
available, slow-release polymer formulation, 90% of the 
sirolimus contained on the stent is released within 30 days 
(Moses et al 2003). The CYPHER stent was approved for 
clinical use in Europe in April 2002 and in the United States 




Sixty patients were eligible for enrolment if there was 
symptomatic coronary artery disease or positive functional 
testing and angiographic evidence of single- or multi-vessel 
disease with a target lesion stenosis of  75% in a  2.5 mm 
vessel. Patients were excluded if there was left main 
disease ( 50%), recent myocardial infarction (MI), ( 7 
days), contraindications to anti-platelet therapy, or a need 
for  3 stents for 1 target site. Every patient signed an 
informed consent.
Stent description and implantation
Meo:DrugStar ST is a commercially available stainless 
steel, paclitaxel-coated stent produced in different sizes. 
Before stenting, all patients were administered clopidogrel 
75 mg/day for 4 days. Procedures were performed using 
the standard angioplasty technique with a 7 and 8 French 
(Fr) guiding catheter via the femoral approach. A bolus of 
100 IU/kg of heparin was administered intra-arterially after 
insertion of the vascular access sheath. Target lesions were 
initially treated with appropriate balloon dilatation. The ref-
erence diameter of target vessel was estimated visually, and 
stent size was determined based on a stent-to-artery ratio of 
1.1:1 to 1.2:1. The stents were deployed at 8–14 atmospheres 
(atm) and high-pressure balloon inﬂ  ation (to 14 atm) was 
then applied with a non-compliant short balloon to avoid 
distal dissection.
Figure 1 The Meo:DrugStar ST stent.Vascular Health and Risk Management 2008:4(1) 175
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Post-procedure medication protocol 
and medication and follow-up
After successful stent implantation, heparin was not routinely 
administered unless there was a clinical indication, such as 
large residual dissection. Femoral sheaths were removed 2 
hours after the procedure. Aspirin 100–300 mg once daily 
and clopidogrel 75 mg once daily were continued 6 months. 
Electrocardiograms (ECGs) were recorded immediately after 
the procedures, then daily before discharge. If the patient 
had recurrent chest pain after the procedure, troponin T and 
CK-MB levels were measured and an additional ECG was 
recorded. The majority of patients were discharged 2 days 
after the procedure. Follow-up coronary angiography was 
performed at 6 months.
Angiographic analysis
Quantitative coronary angiographic analysis was performed 
using the quantitative coronary analysis system (Acom.
PC Lite version 2.0 Siemens München, Germany) at the 
Coronary Angiography Laboratory of the Cardiology 
Department of Izzet Baysal Medical Faculty of Abant 
Izzet Baysal University. Angiographic measurements were 
obtained during end-diastole using the image that showed 
the greatest narrowing, without overlap and with the least 
degree of foreshortening. Measurements of the reference 
vessel diameter, minimal lumen diameter (MLD), and per-
cent diameter stenosis were determined by the average of 
two orthogonal views. The index reference diameter was the 
average of proximal and distal reference vessel diameters. 
Lesion length was measured on the baseline angiography 
using the “shoulder-to-shoulder” deﬁ  nition. Lesions were 
characterized according to the modiﬁ  ed American College 
of Cardiology/American Heart Association (ACC/AHA) 
classiﬁ  cation. Changes in MLD were expressed as acute 
gain (post-procedural MLD minus pre-procedural MLD), 
late loss (post-procedural MLD minus 6-month follow-
up MLD), net gain (acute gain minus late loss), and loss 
index (late loss/acute gain). Angiographic restenosis was 
deﬁ  ned as re-narrowing of the target lesion  50% based 
on a single worst view.
Data collection and statistics
Demographic, clinical, and technical data were prospectively 
entered into a computerized database. All patients were 
interviewed and examined monthly. Follow-up coronary 
angiography was performed 6 months after the procedure. 
If a revascularization procedure involving the target site 
had been performed before the 6-month control-angiography, 
the ﬁ  ndings of the most recent angiography ( 2 months after 
the initial procedure) were used as data for follow-up.
Statistical analysis was performed with SPSS 11.0 for 
Windows (Statistical Package for Social Sciences). Continu-
ous variables were expressed as mean ± SD. Restenosis was 
considered as a categorical variable and categorical variables 
were compered using chi-square test (diabetes mellitus, 
hyperlipidemia, lesion complexity, and stent size of 4.0 or 
more vs smaller stents).
Results
From May 2005 to April 2006 60 patients were selected for 
implantation with a Meo:DrugStar ST stent. The stents were 
implanted successfully in 60 patients with 60 different lesions. 
Mean age (years) was 58 ± 11. There was a high proportion 
of patients with hypertension (55%) according to JNC-VII. 
Prevalence of patients with diabetes mellitus was 35% and 42% 
of patients had hyperlipidemia. Baseline clinical characteristics 
were summarized in Table 1 and lesion baseline angiographic 
characteristics were summarized in Table 2.
Table 1 Baseline clinical characteristics of patients (n = 60)
Characteristics Number  Percent  (%)
Age (years)  58 ± 11
Male/female 32/28  54/46
Hypertension 33  55
Diabetes mellitus  21  35
History of smoking  26  43
Family history  33  55
Hyperlipidemia 25  42
Previous MI  12  20
Previous PCI  10  16
Previous CABG  2  3
Abbreviations: CABG, coronary artery bypass surgery; MI, myocardial infarction; 
PCI, percutaneous coronary intervention.
Table 2 Baseline angiographic characteristics (n = 60 lesions)
Characteristics Number  Percent  (%)
Target coronary artery  
LAD 39  53
Cx 8  13
RCA 13  22
Lesion morphology
Eccentric 32  53
Concentric 27  45
Total occlusion  1  2
Segmenter 7  11
Bifurcation 3  5
Stent restenosis  2  3 
Abbreviations: Cx, left circumﬂ  ex artery; LAD, left anterior descending artery; 
RCA, right coronary artery.Vascular Health and Risk Management 2008:4(1) 176
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All lesions were implanted with a Meo:DrugStar ST stent 
successfully and the device success rate was 100%. There was 
no stent thrombosis in the acute and late follow-up period. 
Mean stenosis ratio was 78 ± 13%, mean implanted stent 
diameter was 3.0 ± 0.4 mm and mean length was 22 ± 5 mm. 
Control coronary angiography was performed for 40 patients 
in a mean of 199 ± 43 days. Restenosis was detected in 4 
(10%) of those patiens and 11 (27.5%) of 40 patients had 
insigniﬁ  cant amount of restenosis. Control coronary angi-
ography was not performed for 20 patients since they did 
not have any cardiac complaints. When we thought the 
asymptomatic patients as being free of signiﬁ  cant restenosis, 
we found the restenosis rate as 7.5%. While the mean stent 
length was 22.8 ± 5.7 mm in the restenosis group, it was 
21.7 ± 5.1 mm in the other patients. While the mean stent 
diameter was 2.9 ± 0.2 mm in the restenosis groups, it was 
3.0 ± 0.4 mm in the other patients.
Discussion
Angiographic and clinical outcome is favorable when per-
cutaneous transluminal angioplasty is combined with stent 
implantation (Serruys et al 1994). Restenosis rates were 
especially lower with balloon expandable stent implantation 
compared with balloon angioplasty in patients with coronary 
artery disease. The search for a better stent that has the most 
favorable results continues.
A breakthrough occurred in early 2000 with the devel-
opment of stents that eluted pharmacology agents directly 
into the vessel wall by means of a controlled release from a 
durable polymer coating.
The European extension to SIRIUS, known as E-SIRIUS, 
enrolled 352 patients who had single native coronary lesions 
with a vessel diameter 2.5–3.0 mm and lesion length 15–32 
mm. Patients were assigned randomly to treatment with 
SES or a bare metal stent (BMS). The binary angiographic 
restenosis rate 8 months later was reduced signiﬁ  cantly in the 
sirolimus-eluting stents (SES) group (5.9% versus 42.3% in 
the BMS group; p = 0.0001) (Schofer et al 2003).
The binary angiographic restenosis rate 6 months later in 
our study with Meo:DrugStar ST stents was 10%. Taking into 
consideration the symptom-free patients who did not come 
for control coronary angiography after 6 months, who had a 
non-signiﬁ  cant restenosis rate, the restenosis rate could be 
accepted as 7.5%.
The results of this study indicate a potential beneﬁ  t of the 
Meo:DrugStar ST stent for the prevention of stent thrombosis 
and restenosis in these relatively high-risk patients.
Study limitations
This study is an open, non-randomized, single-centre, pro-
spective trial and we conclude that the Meo:DrugStar ST stent 
is a safe and effective choice with a low incidence of major 
adverse cardiac events and restenosis rate within 6 months of 
follow-up. The most important limitation of this study was 
the absence of intravascular ultrasound analysis, from which 
one can get more accurate quantitative data. Therefore, our 
results should be compared with larger-scale, randomized 
studies with other stent types.
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